Board Appointment
James Cropper Plc, the advanced materials and speciality paper group today announces the appointment of Dr Andrew Hosty to the Board as a Non-Executive Director with immediate effect. Dr Hosty has been acting as a consultant to the Board since November 2017.
Following a PhD in Materials Technology, Dr Hosty pursued a career in industry culminating in his appointment as CEO of Morgan Ceramics and COO of Morgan Advanced Materials PLC. Most recently he was founding CEO of The Sir Henry Royce Institute for Advanced Materials, a new £235 million centre for UK advanced materials research and innovation.
Commenting on Andrew's appointment, Mark Cropper, Chairman, said: “We are delighted to welcome Andrew to the Board. He has a significant range of relevant experience from materials science to managing high growth companies in related sectors. He has much to contribute to James Cropper Plc as it innovates and grows in the coming years and we are very pleased he is joining us at this exciting time”.
Additional information to be disclosed pursuant to Schedule 2(g) and Rule 17 of the AIM Rules in relation to Dr Andrew Hosty:
In the past five years, Andrew Joseph Hosty (aged 53) has held the following director roles:
|
Company Name |
Position |
From |
To |
|
RHI Magnesita Plc |
Non-Executive Director |
Oct 2017 |
Current |
|
Rights and Issues Investment Trust Plc |
Non-Executive Director |
July 2017 |
Current |
|
mOm Incubators Ltd |
Non-Executive Chairman |
Mar 2017 |
Current |
|
Consort Medical Plc |
Non-Executive Director |
July 2014 |
Current |
|
Morgan Advanced Materials Plc |
Chief Operating Officer |
July 2010 |
Jan 2016 |
|
Morgan Technical Ceramics Ltd |
Director |
July 2000 |
Oct 2015 |
|
Thermal Ceramics UK Ltd |
Director |
Oct 2010 |
Oct 2015 |
|
Certech International Ltd |
Director |
Mar 2010 |
Oct 2015 |
|
Morgan Electro Ceramics Ltd |
Director |
Mar 2010 |
Oct 2015 |
|
British Ceramic Research |
Director |
Sept 2007 |
Jun 2015 |
|
Fiberweb Ltd |
Director |
Sept 2012 |
Nov 2013 |
Dr Hosty holds 500 ordinary shares of 25p each in the Company, representing 0.005% of the Company's issued share capital.
Other than the information contained within this announcement, there are no further disclosures to be made in relation to Dr Hosty under Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies.